Table 2

Characteristics of trials of TENS for pain relief in patients with knee osteoarthritis

First author, publication year

Type

No of patients on active therapy (n = 259)

Method quality

Treat-ment period (weeks)

Mean baseline pain (mm VAS)

Best mean difference (95% CI) of change over placebo (mm VAS)

Outcome time points (in weeks, max. effect in bold)


Adedoyin-03

IF

15

3

4

81.0

25.4 (8.2 to 42.6)

1, 2, 3,4

Cheing-02

TENS

16

4

2

-

8.4 (0.7 to 16.1)

2, 4

Cheing-03

TENS

30

3

2

50.3

32.2 (23.9 to 40.5)

4, 8

Defrin-05

IF

45

4

4

71.0

41.6 (33.4 to 49.8)

4

Fargas-Babjak-89

TENS

19

3

12

-

45.3 (11.7 to 78.9)

6, 12

Law-05

ALTENS/TENS

27

4

2

57.3

29.7 (7.6 to 51.3)

2, 4

Lewis-84**

TENS

29

3

3

-

7.0 (-5.6 to 19.6)

3

Lewis-94**

TENS

28

1

3

-

4.9 (-8.4 to 18.3)

3

Smith-83

TENS

15

3

4

-

dichotomous data only

4

Taylor-81**

TENS

10

2

2

-

5.5 (-7.3 to 17.8)

2

Yurtkuran-99

ALTENS

25

3

2

-

20.0 (14.1 to 25.9)

2

Best within 4 weeks, all trials

223

18.8 (9.6 to 28.1)

Best within 4 weeks, optimal trials

156

22.2 (18.1 to 26.3)

8 weeks

30

8.3 (-1.1 to 17.6)

Global improvement 8 weeks

15

1.8 (0.6 to 4.8) Relative Risk

Overall

259

3.3*

63.8†

2.8*


*Mean † Weighted mean – Not Available ** Trials with non-optimal treatment

Bjordal et al. BMC Musculoskeletal Disorders 2007 8:51   doi:10.1186/1471-2474-8-51

Open Data